Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjogren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers Shares of Aldeyra Therapeutics Inc. (ALDX) jumped nearly 53% to $6.50 in premarket trading on Tuesday, Sept. 12, after the Lexington, Mass.-based firm unveiled positive results from its Phase 2a study of ADX-102 in dry eye disease.
Short @ $6.70 & might hold it for couple days Back to say never mind - chickened out & didn't cover in $6.40's but covered $6.50. Back on watch for better short
